Evaluation of maculopathy in patients using hydroxychloroquine

ArticleAçık Erişim

Özet

Objectives: To determine length of hydroxychloroquine use and cumulative dose and evaluate the ocular effects by 10-2 central visual field test, microperimetry (MP), color fundus photography, optical coherence tomography (OCT), and fundus autofluorescence (FAF) in hydroxychloroquine users. Materials and Methods: Patients who used hydroxychloroquine continuously for at least 2 years for various connective tissue diseases were included in the study. A total of 300 eyes of 150 patients aged 19-78 years who were followed due to risk of developing hydroxychloroquine maculopathy in the İstanbul University İstanbul Faculty of Medicine Ophthalmology Department between the years 1995-2017 were evaluated. Best corrected visual acuity (BCVA), biomicroscopic, and fundoscopic examination were performed at all visits. MP, FAF, OCT, fundus photography, and central 10-2 visual field examinations were performed 3 times at 6-month intervals. Results: The mean age of patients was 48.9±10.8 years; 141 (94%) patients were female and 9 (6%) were male. The mean duration of hydroxychloroquine use was 10.5±6.4 (2-30) years. Fifty-six patients had been using the drug for 5 years or less. The mean cumulative drug dose was 754.7±447.2 (146-1825) g. Mean BCVA was 0.02±0.08 LogMAR at all follow-up visits (p=0.999). Mean MP values at the first, second, and third examinations were 14.07±3.24 dB, 14.18±3.35 dB, and 14.54±2.79 dB, respectively (p>0.05). Mean central macular thickness was 221.9±19.8 µm at initial examination, 221.8±19.9 µm at the second visit, and 221.8±19.8 µm at the final visit (p=0.113). There was a weak negative correlation between age and MP values at all three visits (visit 1: p=0.003, r=-0.170; visit 2: p=0.001, r=-0.185, visit 3: p=0.011, r=-0.146). There was statistically significant relationship between MP values and hydroxychloroquine length of use and cumulative dose (p=0.027 and p=0.049, respectively). Duration of use was not associated with changes in 10/2 visual field (p=0.124). There were significant relationships between alterations in FAF and hydroxychloroquine length of use and cumulative dose (p=0.027 and p=0.049, respectively). Conclusion: FAF alterations were significantly associated with duration of hydroxychloroquine use and cumulative dose. As objective methods are more reliable, examinations such as FAF can be recommended as auxiliary methods in the follow-up and early detection of toxic maculopathy. © 2019 by Turkish Ophthalmological Association.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13669Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorUğurlu, Adem
dc.contributor.authorAslanova, Maisa
dc.contributor.authorCebeci, Zafer
dc.contributor.authorMercül, Nur Kır
dc.date.accessioned2026-10-18T20:28:30.094231675Z
dc.date.available2026-10-18T20:28:30.094231675Z
dc.date.issued2019
dc.description.abstractObjectives: To determine length of hydroxychloroquine use and cumulative dose and evaluate the ocular effects by 10-2 central visual field test, microperimetry (MP), color fundus photography, optical coherence tomography (OCT), and fundus autofluorescence (FAF) in hydroxychloroquine users. Materials and Methods: Patients who used hydroxychloroquine continuously for at least 2 years for various connective tissue diseases were included in the study. A total of 300 eyes of 150 patients aged 19-78 years who were followed due to risk of developing hydroxychloroquine maculopathy in the İstanbul University İstanbul Faculty of Medicine Ophthalmology Department between the years 1995-2017 were evaluated. Best corrected visual acuity (BCVA), biomicroscopic, and fundoscopic examination were performed at all visits. MP, FAF, OCT, fundus photography, and central 10-2 visual field examinations were performed 3 times at 6-month intervals. Results: The mean age of patients was 48.9±10.8 years; 141 (94%) patients were female and 9 (6%) were male. The mean duration of hydroxychloroquine use was 10.5±6.4 (2-30) years. Fifty-six patients had been using the drug for 5 years or less. The mean cumulative drug dose was 754.7±447.2 (146-1825) g. Mean BCVA was 0.02±0.08 LogMAR at all follow-up visits (p=0.999). Mean MP values at the first, second, and third examinations were 14.07±3.24 dB, 14.18±3.35 dB, and 14.54±2.79 dB, respectively (p>0.05). Mean central macular thickness was 221.9±19.8 µm at initial examination, 221.8±19.9 µm at the second visit, and 221.8±19.8 µm at the final visit (p=0.113). There was a weak negative correlation between age and MP values at all three visits (visit 1: p=0.003, r=-0.170; visit 2: p=0.001, r=-0.185, visit 3: p=0.011, r=-0.146). There was statistically significant relationship between MP values and hydroxychloroquine length of use and cumulative dose (p=0.027 and p=0.049, respectively). Duration of use was not associated with changes in 10/2 visual field (p=0.124). There were significant relationships between alterations in FAF and hydroxychloroquine length of use and cumulative dose (p=0.027 and p=0.049, respectively). Conclusion: FAF alterations were significantly associated with duration of hydroxychloroquine use and cumulative dose. As objective methods are more reliable, examinations such as FAF can be recommended as auxiliary methods in the follow-up and early detection of toxic maculopathy. © 2019 by Turkish Ophthalmological Association.
dc.identifier.doi10.4274/tjo.galenos.2018.67864
dc.identifier.eissn2147-2661
dc.identifier.endpage153
dc.identifier.issn2149-8709
dc.identifier.issue3
dc.identifier.pmcidPMC6624465
dc.identifier.pmid31245977
dc.identifier.scopus2-s2.0-85069006346
dc.identifier.startpage149
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13669
dc.identifier.volume49
dc.identifier.wosWOS:000473180100007
dc.language.isoen
dc.publisherTurkish Ophthalmology Society
dc.relation.ispartofTurkish Journal of Ophthalmology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCumulative
dc.subjectDose
dc.subjectFundus autofluorescence
dc.subjectHydroxychloroquine
dc.subjectMaculopathy
dc.subjectAdult
dc.subjectAged
dc.subjectAntirheumatic Agents
dc.subjectConnective Tissue Diseases
dc.subjectFemale
dc.subjectFluorescein Angiography
dc.subjectFollow-Up Studies
dc.subjectFundus Oculi
dc.subjectHumans
dc.subjectIncidence
dc.subjectMacula Lutea
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRetinal Diseases
dc.subjectRetinal Ganglion Cells
dc.subjectRetrospective Studies
dc.subjectTime Factors
dc.subjectTomography, Optical Coherence
dc.subjectTurkey
dc.subjectVisual Acuity
dc.subjectVisual Fields
dc.subjectYoung Adult
dc.subjectantirheumatic agent
dc.subjectArticle
dc.subjectbest corrected visual acuity
dc.titleEvaluation of maculopathy in patients using hydroxychloroquine
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus2
rdl.citation.trdizin1
rdl.citation.wos4
rdl.departmentERZİNCAN BİNALİ YILDIRIM ÜNİVERSİTESİ
rdl.departmentİSTANBUL ÜNİVERSİTESİ
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexTRDIZIN
rdl.source.indexPUBMED
rdl.wos.indexEmerging Sources Citation Index (ESCI)